Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Sai Heng Hao, Lin Yan Ye & Chang Yang. (2023) The landscape of pathophysiology guided therapeutic strategies for gout treatment. Expert Opinion on Pharmacotherapy 0:0, pages 1-11.
Read now
Read now
Federica Piani, Davide Agnoletti & Claudio Borghi. (2023) Advances in pharmacotherapies for hyperuricemia. Expert Opinion on Pharmacotherapy 24:6, pages 737-745.
Read now
Read now
Khedidja Benarous, Fatima Zohra Benali, Ikram Cherifa Bekhaoua & Mohamed Yousfi. (2021) Novel potent natural peroxidases inhibitors with in vitro assays, inhibition mechanism and molecular docking of phenolic compounds and alkaloids. Journal of Biomolecular Structure and Dynamics 39:18, pages 7168-7180.
Read now
Read now
David Fitz-Patrick, Kent Roberson, Kiyoshi Niwa, Takabumi Fujimura, Koji Mori, Jesse Hall, Xiaohong Yan, Zancong Shen, Sha Liu, Yasushi Ito & Scott Baumgartner. (2019) Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials. Modern Rheumatology 29:6, pages 1042-1052.
Read now
Read now
Yue Dong, Tong Zhao, Wei Ai, Waleed A. Zalloum, Dongwei Kang, Ting Wu, Xinyong Liu & Peng Zhan. (2019) Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016–2019). Expert Opinion on Therapeutic Patents 29:11, pages 871-879.
Read now
Read now
Larysa Strilchuk, Federica Fogacci & Arrigo Fg Cicero. (2019) Safety and tolerability of available urate-lowering drugs: a critical review. Expert Opinion on Drug Safety 18:4, pages 261-271.
Read now
Read now
Jesse Hall, Michael Gillen, Sha Liu, Jeffrey N Miner, Shakti Valdez, Zancong Shen & Caroline Lee. (2018) Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects. Drug Design, Development and Therapy 12, pages 1799-1807.
Read now
Read now
Tristan Pascart & Pascal Richette. (2018) Investigational drugs for hyperuricemia, an update on recent developments. Expert Opinion on Investigational Drugs 27:5, pages 437-444.
Read now
Read now
Philip C Robinson & Nicola Dalbeth. (2017) Lesinurad for the treatment of hyperuricaemia in people with gout. Expert Opinion on Pharmacotherapy 18:17, pages 1875-1881.
Read now
Read now
Articles from other publishers (18)
Joanna Parkinson, Corina Dota, Christian Källgren, Christer Gottfridsson, Magnus Bjursell, Shira Perl, Thomas Kӧrnicke, Dinko Rekić & Susanne Johansson. (2023) Verinurad does not prolong QTc interval: a thorough QT study using concentration–QTc modelling. British Journal of Clinical Pharmacology 89:6, pages 1747-1755.
Crossref
Crossref
Ziyu Guo, Wenjing Yuan, Xinru Zhu, Zhenzhou Jiang, Zunjian Zhang & Xin Huang. (2022) UHPLC–MS/MS‐based method for quantification of verinurad in rat plasma and its application in a bioavailability study. Biomedical Chromatography 36:11.
Crossref
Crossref
Christopher Jenkins, Jennifer H. Hwang, Jeffrey B. Kopp, Cheryl A. Winkler & Sung Kweon Cho. (2022) Review of Urate-Lowering Therapeutics: From the Past to the Future. Frontiers in Pharmacology 13.
Crossref
Crossref
Masayuki Hakoda & Kimiyoshi Ichida. (2022) Genetic Basis of the Epidemiological Features and Clinical Significance of Renal Hypouricemia. Biomedicines 10:7, pages 1696.
Crossref
Crossref
Susanne Johansson, David Han, Thomas Hunt, Karin Björck, Delia Florica, Michael Gillen, Jesse Hall & Fredrik Erlandsson. (2022) Pharmacokinetics, pharmacodynamics, and safety of verinurad with and without allopurinol in healthy Asian, Chinese, and non‐Asian participants. Pharmacology Research & Perspectives 10:3.
Crossref
Crossref
A. A. Garanin, N. L. Novichkova & N. L. Novichkova. (2022) Prospects of anti-inflammatory and urate-lowering therapy of gout: A vector from the past to the future. Rheumatology Science and Practice 60:2, pages 205-213.
Crossref
Crossref
Ze-an Zhao, Yu Jiang, Yan-yu Chen, Ting Wu, Qun-sheng Lan, Yong-mei Li, Lu Li, Yang Yang, Cui-ting Lin, Ying Cao, Ping-zheng Zhou, Jia-yin Guo, Yuan-xin Tian & Jian-xin Pang. (2021) CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia. Acta Pharmacologica Sinica 43:1, pages 121-132.
Crossref
Crossref
Danni Song, Xu Zhao, Fuqi Wang & Gang Wang. (2021) A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: Current therapeutic options and potential applications. European Journal of Pharmacology 907, pages 174291.
Crossref
Crossref
V. Sashi Gopaul, Anna Vildhede, Tommy B. Andersson, Fredrik Erlandsson, Caroline A. Lee, Susanne Johansson & Constanze Hilgendorf. (2021) In Vitro Assessment of the Drug–Drug Interaction Potential of Verinurad and Its Metabolites as Substrates and Inhibitors of Metabolizing Enzymes and Drug Transporters. Journal of Pharmacology and Experimental Therapeutics 378:2, pages 108-123.
Crossref
Crossref
Austin G. Stack, Nalina Dronamraju, Joanna Parkinson, Susanne Johansson, Eva Johnsson, Fredrik Erlandsson & Robert Terkeltaub. (2021) Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial. American Journal of Kidney Diseases 77:4, pages 481-489.
Crossref
Crossref
Arrigo F. G. Cicero, Federica Fogacci, Masanari Kuwabara & Claudio Borghi. (2021) Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update. Medicina 57:1, pages 58.
Crossref
Crossref
Christopher Estiverne & David B. Mount. (2020) The Management of Gout in Renal Disease. Seminars in Nephrology 40:6, pages 600-613.
Crossref
Crossref
Jesse Hall, Michael Gillen, Xiaojuan Yang & Zancong Shen. (2018) Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers. Clinical Pharmacology in Drug Development 8:2, pages 179-187.
Crossref
Crossref
Masanari Shiramoto, Sha Liu, Zancong Shen, Xiaohong Yan, Amy Yamamoto, Michael Gillen, Yasushi Ito & Jesse Hall. (2018) Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study. Rheumatology 57:9, pages 1602-1610.
Crossref
Crossref
Martin Kankam, Jesse Hall, Michael Gillen, Xiaojuan Yang, Zancong Shen, Caroline Lee, Sha Liu, Jeffrey N. Miner, Susan Walker, Vicki Clauson, David Wilson & Mai Nguyen. (2018) Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout. The Journal of Clinical Pharmacology 58:9, pages 1214-1222.
Crossref
Crossref
William B. Smith, Jesse Hall, Jolene K. Berg, Michal Kazimir, Amy Yamamoto, Susan Walker, Caroline A. Lee, Zancong Shen, David M. Wilson, Dongmei Zhou, Michael Gillen & Thomas C. Marbury. (2018) Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor. Clinical Drug Investigation 38:8, pages 703-713.
Crossref
Crossref
Caroline L. Benn, Pinky Dua, Rachel Gurrell, Peter Loudon, Andrew Pike, R. Ian Storer & Ciara Vangjeli. (2018) Physiology of Hyperuricemia and Urate-Lowering Treatments. Frontiers in Medicine 5.
Crossref
Crossref
Caroline A. Lee, Chun Yang, Vishal Shah, Zancong Shen, David M. Wilson, Traci M. Ostertag, Jean-Luc Girardet, Jesse Hall & Michael Gillen. (2018) Metabolism and Disposition of Verinurad, a Uric Acid Reabsorption Inhibitor, in Humans. Drug Metabolism and Disposition 46:5, pages 532-541.
Crossref
Crossref